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Background/aim: The aim of this study was to investigate the importance of preprocedural uric acid (UA) level in predicting fractional
flow reserve (FFR) results of intermediate coronary lesions in patients with stable coronary artery disease undergoing coronary
angiography.
Materials and methods: We retrospectively analyzed 293 patients who underwent FFR measurement to determine the significance of
intermediate coronary stenosis detected by conventional coronary angiography. Patients were divided into 2 groups: Group 1 (n = 127)
included patients with FFR of <0.80 (hemodynamically significant lesions), and Group 2 (n = 169) consisted of patients with FFR of
>0.80 (hemodynamically nonsignificant lesions). Uric acid levels were assessed in both groups with the enzymatic colorimetric method
by clinical chemistry autoanalyzer.
Results: The mean UA level was significantly higher in patients whose FFR indicated hemodynamically significant coronary lesions
(UA: 5.43 ± 1.29 mg/dL in Group 1 vs. 4.51 ± 1.34 mg/dL in Group 2, P < 0.001).
Conclusion: Elevated UA levels are associated with hemodynamically significant coronary lesions measured with FFR. Uric acid may
be used as a predictor of hemodynamically compromised coronary lesions before FFR procedures.
Key words: Uric acid, fractional flow reserve, intermediate coronary stenosis

1. Introduction
Determining the functional significance of a coronary
artery lesion is essential for revascularization decisions
and prognosis estimation in patients with coronary
artery disease (CAD). Coronary angiography (CAG)
plays a crucial role in the assessment of coronary artery
stenosis. However, it is inherently limited in its ability to
demonstrate the functional significance of a coronary
lesion, particularly in intermediate lesions, defined as
those with 50%–70% stenosis [1]. Fractional flow reserve
(FFR) is the most accurate method of determining the
physiological significance of a coronary lesion and is
therefore an important technique in daily cardiology
practice [2].
Uric acid (UA) is an end-product of purine
metabolism. There is growing evidence that elevated UA
levels are correlated with both cardiovascular disease
and its leading risk factors, such as hypertension [3].
Recent studies suggested that UA may be associated with

endothelial dysfunction, oxidative stress, vasoconstriction,
and inflammation, all of which are important in the
development and progression of CAD [4,5]. Furthermore,
UA elevation was shown to be positively correlated with
CAD severity [6] and it may have a role in the prediction
of prognosis after percutaneous coronary intervention in
stable CAD [7]. Despite studies suggesting a link between
UA and CAD, the relationship between UA and the
functional significance of coronary lesions has yet to be
determined.
The aim of this study was to investigate the significance
of preprocedural UA level as a predictor of FFR results in
patients with stable CAD undergoing CAG.
2. Materials and methods
A total of 293 consecutive patients who underwent
FFR measurement to determine the significance of
intermediate coronary stenosis detected by conventional
CAG were included in this retrospective study. Patients
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with acute coronary syndrome with or without positive
cardiac markers, glomerular filtration rate of <60 mL/
min, malignancy, hematological disorders, history of gout,
ongoing treatment affecting UA levels such as allopurinol,
chronic inflammatory diseases, or active infection were
excluded from the study. Clinical risk factors such as age,
sex, smoking status, diabetes mellitus (DM), hypertension,
low-density lipoprotein (LDL) levels, and obesity were
recorded. Written informed consent was obtained from
each patient and the study was approved by the institutional
ethics committee.
2.1. Laboratory testing
Blood samples were collected from the antecubital vein
after 12 h of overnight fasting within 1 week before
the procedure. Routine biochemistry and hemogram
parameters were obtained. Uric acid levels were measured
with the enzymatic colorimetric method by a clinical
chemistry autoanalyzer (Aeroset, Abbott Laboratory,
Abbott Park, IL, USA).
2.2. Coronary angiography and fractional flow reserve
The standard Judkins technique via femoral approach
was used for coronary artery visualization. All patients
were referred for elective coronary artery angiography
by their attending physicians, who were blind to the
study’s aim. Coronary angiography was performed using
the DFP-8000D Toshiba digital radiography system.
Intermediate coronary stenosis was defined as 50%–70%
stenosis in any epicardial coronary artery (i.e. left anterior
descending, circumflex, or right coronary artery). The
SYNTAX I score was calculated using the SYNTAX score
website (http://www.syntaxscore.com) by 2 interventional
cardiologists who were blinded to the patients and
each other. Measurement of fractional flow reserve was
performed with a Radi 0.014 XT PW pressure-monitoring
guidewire. After the pressure guidewire was calibrated and
positioned distal to the lesion, an intracoronary adenosine
bolus (initially 150 µg for the left coronary system vs. 100
µg for the right coronary artery) was administered to
induce maximal vasodilatation by successively increasing
the adenosine dose (maximum 600 µg) until no further
decrement in FFR value was observed. Fractional flow
reserve values were calculated as the ratio of mean distal
coronary artery pressure to aortic pressure during basal
and maximal vasodilatation. An FFR value of <0.80
after maximal hyperemia with adenosine was defined as
hemodynamically significant. ∆FFR was measured using
the following formula: FFRrest − FFRhyperemia.

2.3. Statistical analysis
SPSS 21.0 for Windows (IBM Corp., Armonk, NY, USA)
was used in all statistical analyses. The variables were
investigated using visual (histograms, probability plots)
and analytical (Kolmogorov–Smirnov test) methods

to determine whether they were normally distributed.
Descriptive analyses were presented using means and
standard deviations for normally distributed variables
and medians and interquartile range for nonnormally
distributed variables. Categorical variables were presented
as numbers and percentages. Student’s t-test or the
Mann–Whitney U test were used to compare continuous
variables, while the chi-square test and Fisher’s exact test,
if necessary, were used to identify statistical differences
for categorical variables. Pearson’s correlation analysis
was used to assess correlations between UA and other
parameters. Stepwise multivariate logistic regression
analysis was done to examine the association between the
functional significance of the lesions and other variables.
Variables with P < 0.25 in univariate logistic regression
were included in a multivariate logistic regression model.
In the logistic regression model, UA level was assumed to
be a binary variable according to the cutoff point detected
in the receiver operating characteristic (ROC) curve
analysis. P < 0.05 was defined as statistically significant.
3. Results
Baseline characteristic features are shown in Table 1. The
293 patients in the study were divided into two groups:
those with FFR values of <0.80 (Group 1, n = 127) and
those with FFR values of ≥0.80 (Group 2, n = 169) after
adenosine infusion. The mean age of the participants
was 61.5 ± 9.3 years and 65.5% were male. The groups
were similar in terms of age, sex, and prevalence of DM,
hypertension, and smoking status. The mean UA level
was significantly higher in group 1 (5.43 ± 1.29 vs. 4.51 ±
1.34 mg/dL, P < 0.001). The lactose dehydrogenase (LDH)
level was also significantly higher in Group 1, whereas red
blood cell (RBC) count and hemoglobin (Hb) level were
higher in Group 2.
There was no significant correlation between UA level
and SYNTAX I score (P = 0.136, r = 0.087). Baseline FFR
before adenosine was significantly lower in Group 1 than
Group 2 (0.87 ± 0.04 vs. 0.93 ± 0.03, P < 0.001). There
was a weak but significant positive correlation between
UA level and ∆FFR (r = 0.221, P < 0.001) (Table 2). ROC
curve analysis revealed that a UA cutoff point of 4.95 mg/
dL had 65.1% sensitivity and 66.5% specificity in detecting
significant functional stenosis in FFR measurements
(Figure). When the patients were grouped according to
this cutoff level, the group with high UA had significantly
lower FFR values at baseline and maximal hyperemia
and significantly greater ∆FFR (Table 2). In multivariate
logistic regression analysis, UA (OR 3.970, CI: 2.383–
6.643, P < 0.001) and RBC count (OR 0.999, CI: 0.999–
1.000, P = 0.007) were identified as independent predictors
of significant functional stenosis (Table 3).
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Table 1. Baseline characteristic features.
Total (n = 293)

Group 1(n = 126)

Group 2 (n = 167)

P-value

Age, years

61.5 ± 9.3

61.1 ± 9

62 ± 9.5

0.471

Sex, male, n (%)

192 (65.5)

90 (71.4)

102 (61)

0.085

Hypertension, n (%)

136 (46.4)

60 (47.6)

76 (45.5)

0.810

Diabetes mellitus, n (%)

114 (38.9)

54 (42.9)

60 (35.9)

0.279

Smoking, n (%)

129 (44.0)

55 (43.7)

74 (44.3)

0.910

BUN, mg/dL

16 (14–20)

16 (14–20)

16.5 (14–20)

0.918

Creatine, mg/dL

0.9 (0.8–1.1)

0.9 (0.8–1.1)

0.9 (0.8–1.1)

0.913

Glucose, mg/dL

111 (95–154)

115 (95–163)

109 (94–146)

0.322

AST, U/L

20 (17–27)

20 (16–26)

21 (17–27)

0.477

ALT, U/L

21 (15–28)

20 (15–29)

21 (15–28)

0.460

Uric acid, mg/dL

4.9 ± 1.4

5.4 ± 1.3

4.5 ± 1.3

<0.001

LDH, U/L

192 (163–225)

204 (170–228)

182 (159–225)

0.048

36 (22–48)

36 (25–50)

36 (21–43)

0.095

WBC, ×10 /mL

8.2 ± 6.6

8.1 ± 2.4

8.3 ± 2.4

0.680

RBC, ×10 /mL

4.6 ± 0.6

4.5 ± 1

4.6 ± 0.6

0.036

Hemoglobin, g/dL

13.6 ± 2.3

13.3 ± 2.1

13.8 ± 2.5

0.049

MCV, fL

88 (85–91)

88 (85–91)

87 (85–91)

0.371

13.8 (13–15)

13.7 (13–15)

13.8 (13–15)

0.792

Platelets, ×10 /mL

240 ± 67.5

241 ± 73

239 ± 63

0.745

MPV, fL

8.7 (8–9.5)

8.6 (7.9–9.5)

8.8 (8–9.6)

0.353

PDW, %

16.6 (16–17)

16.6 (16–17)

16.6 (16–17)

0.170

Total cholesterol, mg/dL

190 ± 54

192 ± 54

188 ± 54

0.497

LDL, mg/dL

118 ± 46

121 ± 45

116 ± 46

0.358

HDL, mg/dL

40 (34–47)

38 (34–46)

41 (34–48)

0.154

Triglyceride, mg/dL

134 (92–207)

136 (97–202)

128 (87–214)

0.713

SYNTAX I score

12.5 ± 7.2

10.8 ± 6.6

14.9 ± 7.5

0.182

GGT, U/L
3

6

RDW, %
3

BUN, Blood urea nitrogen; AST, aspartate transaminase; ALT, alanine transaminase; LDH, lactate dehydrogenase; GGT,
gamma-glutamyl transferase; WBC, white blood cells; RBC, red blood cells; MCV, mean corpuscular volume’ RDW, red
cell distribution width; MPV, mean platelet volume; PDW, platelet distribution width; LDL, low-density lipoprotein;
HDL, high-density lipoprotein.

Table 2. Comparison of fractional flow reserve (FFR) values between the low and high uric acid groups.
Uric acid < 4.95 mg/dL

Uric acid ≥ 4.95 mg/dL

P-value

FFR, baseline

0.91 ± 0.05

0.89 ± 0.05

0.002

FFR, after adenosine

0.82 ± 0.07

0.77 ± 0.08

<0.001

∆FFR

0.09 ± 0.05

0.12 ± 0.06

< 0.001

FFR, Fractional flow reserve.
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Figure. Receiver operating characteristic (ROC) curve analysis of
uric acid level for the detection of significant functional stenosis
in FFR measurements.

4. Discussion
The main finding of the present study is that admission UA
level is significantly and independently associated with the
functional significance of angiographically intermediate
coronary stenosis. To the best of our knowledge, this is
the first study to report such a relationship. Although RBC
count was the other independent predictor of functional
stenosis, an odds ratio of 0.999 means that this association
is unlikely to be of clinical importance.
Intermediate stenosis (50%–70%) is a common
finding in CAG, and deciding whether to pursue medical
or interventional treatment is difficult for such lesions.
Fractional flow reserve is the gold-standard method
for decision-making in intermediate lesions because
it provides precise information about physiological
hemodynamic status rather than a prediction from
anatomical appearance [8]. On the other hand, FFR is
an invasive method with some cost, and more easily
attainable, cheaper, and repeatable markers would be
welcomed. Thus, UA may be a valuable marker for both
diagnosis and treatment decisions.
Studies have revealed that hyperuricemia is associated
with hypertension, atherosclerosis, and even sudden
cardiac death, but its exact relationship with cardiovascular
outcomes remains controversial [9]. Previous studies
showed that high UA level is associated with more
extensive and severe CAD, poorer coronary collateral
circulation, and more coronary calcification, all of which

are related to poor prognosis [10]. Ndrepepa et al. also
showed that higher UA level was a predictor of increased
risk of mortality in 13,723 patients with angiographyproven CAD [11].
The role of uric acid in the formation and progression
of CAD is not well established. However, it was shown
that UA has some mechanical and molecular effects
such as promotion of inflammation, vasoconstriction,
and endothelial dysfunction, which may contribute to
atherosclerosis and related comorbidities such as CAD.
Moreover, hyperuricemia induces oxidative stress by
an unknown mechanism. Antioxidant treatment in
hyperuricemic rats resulted in hypertension remission
and improved proinflammatory effects [5,12]. Uric acid
uptaken by cells stimulates chemokine and inflammatory
marker synthesis, which also leads to activation of
vasoconstrictor mediators such as thromboxane,
endothelin-1, and angiotensin-II [13,14].
Our data showed that a preprocedurally elevated
UA level is associated with hemodynamically significant
lesions measured by FFR during index angiography.
This result is compatible with previous studies that also
reported its correlation with CAD presence and impaired
myocardial perfusion [15,16].
The above-mentioned vasoconstrictor mechanism in
hyperuricemia and its role in atherosclerosis pathogenesis
results in impaired vasorelaxation. Inducing hyperemia is
a key part of the FFR procedure, and hyperuricemia may
affect adenosine-related vasodilation. Higher ∆FFR values
may be attributable to a reversal of baseline hyperuricemiainduced vasoconstriction by adenosine administration.
Hyperuricemia impairs endothelial function in various
ways, especially endothelial-dependent vasodilation,
thus promoting vasoconstriction. Moreover, as adenosine
enhances NO release from the endothelium, endothelial
dysfunction will lead to impaired response to adenosine
challenge, which is also a possible contributor to lower
FFR values. Coronary artery disease causing ischemia
eventually results in ATP reduction in the myocardium.
Studies have shown that ATP depletion may be an
important contributor to uric acid overproduction [17],
which in turn increases apoptosis, oxidative stress, and
a jeopardized myocardium [18]. We suppose that the
relationship between ATP and uric acid level needs to be
investigated.
Patients with FFR values in the gray zone (0.75–0.80)
are the most complicated cases for determining lesion
severity, and thus the most challenging in terms of treatment
decisions. For these patients, Kocaman et al. proposed
using ∆FFR, which is defined as the difference between
resting FFR and FFR after adenosine administration,
and suggested that ∆FFR represents the compensatory
response capacity of the coronary microvasculature [19].
In the present study, higher ∆FFR values were detected in
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Table 3. Factors predicting functional significance in multivariate logistic regression analysis.
Univariate
Variables

Multivariate

OR (95% CI)

P-value

OR (95% CI)

P-value

Age

0.969 (0.940–0.999)

0.046

0.975 (0.948–1.002)

0.073

Male sex

1.557 (0.862–2.811)

0.142

1.606 (0.932–2.767)

0.088

Hypertension

1.308 (0.752–2.273)

0.342

-

-

Diabetes mellitus

1.145 (0.671–1.955)

0.620

-

-

Hemoglobin

0.963 (0.790–1.173)

0.707

-

-

RBC

1.000 (0.999–1.000)

0.181

0.999 (0.999–1.000)

0.007

PDW

1.115 (0.927–1.342)

0.253

-

-

LDH

1.004 (1.000–1.008)

0.069

1.004 (1.000–1.008)

0.066

Uric acid > 4.95 mg/dL

3.738 (2.215–6.306)

<0.001

3.979 (2.383–6.643)

<0.001

HDL

0.989 (0.963–1.016)

0.425

-

-

RBC, Red blood cell; PDW, platelet distribution width; LDH, lactate dehydrogenase; HDL, high-density
lipoprotein.

patients with higher UA levels. Thus, higher UA levels may
be an indicator of severe lesions in the gray zone.
Previous studies have shown positive correlations
between SYNTAX scores and serum uric acid levels, unlike
our study. However, our study involved a population more
likely to have type A lesions and low SYNTAX scores.
These findings may be responsible for this unexpected
result.
Numerous factors influence atherosclerosis and
coronary artery lesion severity. In our patients groups, the
distribution of risk factors and other biochemical markers
(fasting glucose, HbA1c level, creatinine) were similar.
These well-matched groups strengthened the power of our
study, ensuring that UA was the only biochemical and risk
factor difference.
In conclusion, elevated UA level is associated with
hemodynamically significant coronary lesions in FFR.

A significant but weak positive correlation was detected
between UA levels and ∆FFR values. UA may have a role
in the prediction of hemodynamically significant coronary
lesions; however, further studies are needed to validate this
finding in large-scale trials.
4.1. Study limitations
This study has some limitations. First of all, the number of
patients is a major disadvantage and limits the statistical
power of the study. Second, antihypertensive and
antidiabetic medications may influence UA levels. Other
medications affecting endothelial function (statins, ACE
inhibitors) and uric acid level (thiazide diuretics) may also
have a role in vascular response. Third, it is more plausible
to conduct a prospective study to investigate the direct
effect of UA during adenosine administration. Singlecenter trials may not reflect a nationwide and generalized
outcome.
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